No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 2,918 | 4,359 | 5,080 | 4,305 | 3,693 | 3,717 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 505 | 627 | 721 | 763 | 246 | 284 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Valiant Co.,Ltd., a global enterprise established in 1992, specializes in the worldwide production and distribution of an extensive array of chemical materials. The company's diverse product portfolio primarily encompasses electronic chemicals, including components and intermediates vital for liquid crystal displays (LCDs) and organic light-emitting diodes (OLEDs), as well as polyimide (PI) materials, photoresist (PR) monomers, and crucial additives for lithium-ion batteries. Beyond electronics, Valiant provides various specialized materials for environmental and industrial applications. These include substances for automotive exhaust purification, catalysts for flue gas denitrification, volatile organic compound (VOC) adsorption, methanol-to-olefin conversion, and petroleum cracking. Furthermore, the company contributes to the new energy sector with advanced materials, energy-efficient lighting solutions, organic solar technologies, and ancillary components for electric vehicles. Valiant's operations also extend into the life sciences and healthcare domains. It manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and finished drug formulations, alongside traditional Chinese medicine products and nutritional health supplements. The company supports scientific research through life science products and services relevant to drug innovation, genomics, proteomics, metabolomics, and food health analysis. Additionally, Valiant develops diagnostic reagents essential for identifying human diseases such as AIDS, hepatitis, cancer, dengue fever, and cardiovascular/cerebrovascular conditions, as well as for detecting drug abuse, endocrine levels, and other physiological parameters. Originally known as Yantai Valiant Fine Chemicals Co., Ltd., the company rebranded to Valiant Co.,Ltd. in May 2015. It is headquartered in Yantai, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Valiant Co.,Ltd (002643.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Valiant Co.,Ltd., a global enterprise established in 1992, specializes in the worldwide production and distribution of an extensive array of chemical materials. The company's diverse product portfolio primarily encompasses electronic chemicals, including components and intermediates vital for liquid crystal displays (LCDs) and organic light-emitting diodes (OLEDs), as well as polyimide (PI) materials, photoresist (PR) monomers, and crucial additives for lithium-ion batteries. Beyond electronics, Valiant provides various specialized materials for environmental and industrial applications. These include substances for automotive exhaust purification, catalysts for flue gas denitrification, volatile organic compound (VOC) adsorption, methanol-to-olefin conversion, and petroleum cracking. Furthermore, the company contributes to the new energy sector with advanced materials, energy-efficient lighting solutions, organic solar technologies, and ancillary components for electric vehicles. Valiant's operations also extend into the life sciences and healthcare domains. It manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and finished drug formulations, alongside traditional Chinese medicine products and nutritional health supplements. The company supports scientific research through life science products and services relevant to drug innovation, genomics, proteomics, metabolomics, and food health analysis. Additionally, Valiant develops diagnostic reagents essential for identifying human diseases such as AIDS, hepatitis, cancer, dengue fever, and cardiovascular/cerebrovascular conditions, as well as for detecting drug abuse, endocrine levels, and other physiological parameters. Originally known as Yantai Valiant Fine Chemicals Co., Ltd., the company rebranded to Valiant Co.,Ltd. in May 2015. It is headquartered in Yantai, China.